Clinical Trials
3 trialsNCT03075527 2026-01-08
A Phase 2 Study of Durvalumab in Combination With Tremelimumab in Malignant Pleural Mesothelioma
Dana-Farber Cancer Institute
Phase 2 Terminated
NCT02899195 2023-07-05
PrE0505
PrECOG, LLC.
Phase 2 Completed
NCT02592551 2022-09-29
MEDI4736 Or MEDI4736 + Tremelimumab In Surgically Resectable Malignant Pleural Mesothelioma
Baylor College of Medicine
Phase 2 Completed